Inhaled Insulin Ready For Prime-time

Today I started a position in NKTR by purchasing 200 shares at 14.49$.  The thesis is that Pfizer will ramp sales of Exhubra (sp?) in '07 and NKTR will see that partnership show fruit.

I also like MNKD but that order has yet to fill. The two companies have competing products. NKTR is said to be 2 years ahead from and FDA approval perspective but MNKD has a much smaller inhaler. Time will tell who the winner is but I do believe big pharma will look for alternative delivery methods (instead of oral and injection) for many of their drugs that are coming off patent as a means of differentiating from generic competitors.